Wockhardt Group's Zaynich drug, a novel antibiotic combination of Zidebactum and Cefepime, has received fast-track review status from the European Medicines Agency (EMA) for the treatment of serious bacterial infections, including severe urinary infections, hospital-acquired pneumonia, and life-threatening blood infections.
from NDTV Profit https://ift.tt/zMP4ue6
from NDTV Profit https://ift.tt/zMP4ue6
Will Zaynich Drug's Fast-Track Review Speed Europe Approval?
![Will Zaynich Drug's Fast-Track Review Speed Europe Approval?]()
Reviewed by aamira sultan
on
January 01, 2026
Rating:
No comments: